The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma. Objective: To conduct a systematic review and meta-analysis of the effects of SMART in patients with persistent asthma. Data Sources and Study Selection: The databases of MEDLINE via OVID, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched from database inception through August 2016 and updated through November 28, 2017. Two reviewers selected randomized clinical trials or observational studies evaluating SMART vs inhaled corticosteroids with or without a LABA used as the controller therapy and short-acting β-agonists as the relief therapy for patients aged 5 years or older with persistent asthma and reporting on an outcome of interest. Data Extraction and Synthesis: Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs), risk differences (RDs), and mean differences with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength of evidence grading were completed by 2 independent reviewers. Main Outcomes and Measures: Asthma exacerbations. Results: The analyses included 16 randomized clinical trials (N = 22 748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler. Among patients aged 12 years or older (n = 22 524; mean age, 42 years; 14 634 [65%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD, -6.4% [95% CI, -10.2% to -2.6%]) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI, 0.60 to 0.98]; RD, -2.8% [95% CI, -5.2% to -0.3%]). Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy. Among patients aged 4 to 11 years (n = 341; median age, 8 [range, 4-11] years; 69 [31%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with a higher dose of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI, 0.32 to 0.94]; RD, -12.0% [95% CI, -22.5% to -1.5%]) or the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.38 [95% CI, 0.23 to 0.63]; RD, -23.2% [95% CI, -33.6% to -12.1%]). Conclusions and Relevance: In this meta-analysis of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations. Evidence for patients aged 4 to 11 years was limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
A refined method for the meta-analysis of controlled clinical trials with binary outcome
Hartung, J., & Knapp, G. (2001) · Statistics in Medicine · doi:10.1002/sim.1009 · Cited by 775
Validation of a Standardized Version of the Asthma Quality of Life Questionnaire
Juniper, E. F., Buist, A. S., Cox, F. M., Ferrie, P. J., & King, D. R. (1999) · Chest · doi:10.1378/chest.115.5.1265 · Cited by 714
Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
O'Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., & Bateman, E. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-884oc · Cited by 657
The minimally important difference of the Asthma Control Test
Schatz, M., Kosinski, M., Yarlas, A. S., Hanlon, J., Watson, M. E., & Jhingran, P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.053 · Cited by 556
On tests of the overall treatment effect in meta-analysis with normally distributed responses
Hartung, J., & Knapp, G. (2001) · Statistics in Medicine · doi:10.1002/sim.791 · Cited by 543
Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change
Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., & Goodman, S. N. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2886 · Cited by 453
Rabe, K. F., Atienza, T., Magyar, P., Larsson, P., Jorup, C., & Lalloo, U. G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69284-2 · Cited by 431
Asthma outcomes: Exacerbations
Fuhlbrigge, A., Peden, D., Apter, A. J., Boushey, H. A., Camargo, C. A., Gern, J., Heymann, P. W., Martinez, F. D., Mauger, D., Teague, W. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.983 · Cited by 326
Budesonide/Formoterol Maintenance Plus Reliever Therapy
Bisgaard, H., Le Roux, P., Bjåmer, D., Dymek, A., Vermeulen, J. H., & Hultquist, C. (2006) · Chest · doi:10.1378/chest.130.6.1733 · Cited by 315
Asthma Control Questionnaire in children: validation, measurement properties, interpretation
Juniper, E. F., Gruffydd-Jones, K., Ward, S., & Svensson, K. (2010) · European Respiratory Journal · doi:10.1183/09031936.00117509 · Cited by 280
What are minimal important changes for asthma measures in a clinical trial?
Santanello, N. C., Zhang, J., Seidenberg, B., Reiss, T. F., & Barber, B. L. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14a06.x · Cited by 275
Kuna, P., Peters, M. J., Manjra, A. I., Jorup, C., Naya, I. P., Martínez-Jimenez, N. E., & Buhl, R. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01338.x · Cited by 274
Overall asthma control: The relationship between current control and future risk
Bateman, E. D., Reddel, H. K., Eriksson, G., Peterson, S., Östlund, O., Sears, M. R., Jenkins, C., Humbert, M., Buhl, R., Harrison, T. W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.033 · Cited by 258
Jackson, D., Law, M., Rücker, G., & Schwarzer, G. (2017) · Statistics in Medicine · doi:10.1002/sim.7411 · Cited by 249
Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma
Rabe, K. F., Pizzichini, E., Ställberg, B., Romero, S., Balanzat, A. M., Atienza, T., Lier, P. A., & Jorup, C. (2006) · Chest · doi:10.1378/chest.129.2.246 · Cited by 245
Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centanni, S., Boulet, L.-P., Naya, I. P., & Hultquist, C. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2051 · Cited by 233
Bousquet, J., Boulet, L.-P., Peters, M. J., Magnussen, H., Quiralte, J., Martinez-Aguilar, N. E., & Carlsheimer, Å. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.07.014 · Cited by 220
Patel, M., Pilcher, J., Pritchard, A., Perrin, K., Travers, J., Shaw, D., Holt, S., Harwood, M., Black, P., Weatherall, M., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70007-9 · Cited by 207
Papi, A., Corradi, M., Pigeon-Francisco, C., Baronio, R., Siergiejko, Z., Petruzzelli, S., Fabbri, L. M., & Rabe, K. F. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70012-2 · Cited by 170
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
Stempel, D. A., Raphiou, I., Kral, K. M., Yeakey, A. M., Emmett, A. H., Prazma, C. M., Buaron, K. S., & Pascoe, S. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511049 · Cited by 168
Berkman, N. D., Lohr, K. N., Ansari, M., McDonagh, M. S., Balk, E. M., Whitlock, E. P., Reston, J. T., Bass, E. B., Butler, M. E., Gartlehner, G., et al. (2013) · Europe PMC (PubMed Central) · Cited by 157
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma
Stempel, D. A., Szefler, S. J., Pedersen, S., Zeiger, R. S., Yeakey, A. M., Lee, L. A., Liu, A. H., Mitchell, H., Kral, K. M., Raphiou, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606356 · Cited by 148
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone
Peters, S. P., Bleecker, E. R., Canonica, G. W., Park, Y. B., Ramirez, R., Hollis, S., Fjällbrant, H., Jorup, C., & Martin, U. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511190 · Cited by 113
Sovani, M. P., Whale, C. I., Oborne, J., Cooper, S. E., Mortimer, K. J., Ekström, T., Tattersfield, A. E., & Harrison, T. (2007) · British Journal of General Practice · doi:10.3399/bjgp08x263802 · Cited by 83
Hartung–Knapp method is not always conservative compared with fixed‐effect meta‐analysis
Wiksten, A. S., Rücker, G., & Schwarzer, G. (2016) · Statistics in Medicine · doi:10.1002/sim.6879 · Cited by 78
Pavord, I. D., Jeffery, P. K., Qiu, Y., Zhu, J., Parker, D., Carlsheimer, Å., Naya, I. P., & Barnes, N. C. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.034 · Cited by 77
Bateman, E. D., Esser, D., Chirila, C., Fernandez, M., Fowler, A., Moroni-Zentgraf, P., & FitzGerald, J. M. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.023 · Cited by 74
Lundborg, M., Wille, S., Bjermer, L. H., Tilling, B., Lundgren, M., Telg, G., Ekström, T., & Selroos, O. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x100212 · Cited by 66
Morice, A. H., Peterson, S., Beckman, O., & Osmanliev, D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01574.x · Cited by 45
Ställberg, B., Ekström, T., Neij, F., Olsson, P., Skoogh, B., Wennergren, G., & Löfdahl, C.-G. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.017 · Cited by 44
Atienza, T., Aquino, T. O., FERNÁNDEZ, M., Boonsawat, W., KAWAI, M., KUDO, T., Ekelund, J., Ivanov, S., & Carlsson, L. (2012) · Respirology · doi:10.1111/resp.12009 · Cited by 40
Hozawa, S., Terada, M., & Hozawa, M. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.12.003 · Cited by 33
Vogelmeier, C. F., Naya, I., & Ekelund, J. (2012) · Clinical Drug Investigation · doi:10.2165/11598840-000000000-00000 · Cited by 20
Cited by
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Improving lung health in low-income and middle-income countries: from challenges to solutions
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C. E., Bush, A., Celli, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00458-x · Cited by 470
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., Harrison, T., Houghton, C., Oldfield, K., Papi, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901963 · Cited by 466
Reddel, H. K., FitzGerald, J. M., Bateman, E. D., Bacharier, L. B., Becker, A., Brusselle, G., Buhl, R., Cruz, A. A., Fleming, L., Inoue, H., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01046-2019 · Cited by 390
Metadata
- Authors
- Sobieraj, D. M., Weeda, E. R., Nguyen, E., Coleman, C. I., White, C. M., Lazarus, S. C., Blake, K. V., Lang, J. E., & Baker, W. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-04-10
- Volume
- 319
- Issue
- 14
- Pages
- 1485
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2792789739
- Cited by
- 326
- References
- 41
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.